Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 10/20 | 0.34 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.32 |
| ▸ | PTPN6 | P29350 | 2/20 | 0.32 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.32 |
| ▸ | BCHE | P06276 | 1/20 | 0.32 |
| ▸ | SELE | P16581 | 1/20 | 0.31 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | SELP | P16109 | 2/20 | 0.30 |
| ▸ | PRKCA | P17252 | 1/20 | 0.30 |
| ▸ | AKT1 | P31749 | 1/20 | 0.30 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.30 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19767542 | 0.91 | PAX8 (0.36) | PTPN1PAX8LMNAPRKCAAKT1 | |
| SCHEMBL9604548 | 0.90 | PTPN1 (0.35) | PTPN1PTPN2PTPN6PTPN11BCHE | |
| SCHEMBL16299440 | 0.89 | PTPN1 (0.37) | PTPN1PTPN2PTPN6PTPN11PAX8 | |
| SCHEMBL9604465 | 0.87 | LMNA (0.34) | PTPN1PAX8LMNAPRKCAAKT1 | |
| SCHEMBL12211060 | 0.86 | PTPN1 (0.37) | PTPN1PTPN2PTPN6PTPN11PAX8 | |
| SCHEMBL9604484 | 0.85 | LMNA (0.38) | PTPN1PTPN2PTPN6PTPN11SELE | |
| SCHEMBL19767534 | 0.85 | KMT2A (0.36) | PTPN1PTPN2PTPN6PTPN11PAX8 | |
| SCHEMBL10177687 | 0.84 | TSHR (0.41) | PTPN1PAX8LMNAPRKCAAKT1 | |
| SCHEMBL13298881 | 0.84 | ALDH1A1 (0.38) | PTPN1BCHELMNASELPSLC2A1 | |
| SCHEMBL26562238 | 0.83 | PAX8 (0.38) | PTPN1PAX8LMNAPRKCAAKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11666653-B2 | Carbohydrate conjugates as delivery agents for oligonucleotides | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-06-06 | — | — | US | disclosed |
| US-9814777-B2 | Targeting lipids | ARBUTUS BIOPHARMA CORPORATION (CA) | 2017-11-14 | — | — | US | disclosed |
| US-20160375137-A9 | TARGETING LIPIDS | TEKMIRA PHARMACEUTICALS CORPORATION (CA) | 2016-12-29 | — | — | US | disclosed |
| US-9370582-B2 | Carbohydrate conjugates as delivery agents for oligonucleotides | ALNYLAM PHARMACEUTICALS, INC. (US) | 2016-06-21 | — | — | US | disclosed |
| US-9370581-B2 | Carbohydrate conjugates as delivery agents for oligonucleotides | ALNYLAM PHARMACEUTICALS, INC. (US) | 2016-06-21 | — | — | US | disclosed |
| US-9352048-B2 | Carbohydrate conjugates as delivery agents for oligonucleotides | ALNYLAM PHARMACEUTICALS, INC. (US) | 2016-05-31 | — | — | US | disclosed |
| US-9290760-B2 | Modified iRNA agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2016-03-22 | — | — | US | disclosed |
| US-20150119445-A1 | Carbohydrate Conjugates as Delivery Agents for Oligonucleotides | BANK OF AMERICA, N.A. | 2015-04-30 | — | — | US | disclosed |
| US-20150119444-A1 | Carbohydrate Conjugates as Delivery Agents for Oligonucleotides | BANK OF AMERICA, N.A. | 2015-04-30 | — | — | US | disclosed |
| US-20150011615-A1 | Carbohydrate Conjugates as Delivery Agents for Oligonucleotides | BANK OF AMERICA, N.A. | 2015-01-08 | — | — | US | disclosed |
| US-8828956-B2 | Carbohydrate conjugates as delivery agents for oligonucleotides | ALNYLAM PHARMACEUTICALS, INC. (US) | 2014-09-09 | — | — | US | disclosed |
| US-20140179761-A1 | TARGETING LIPIDS | TEKMIRA PHARMACEUTICALS CORPORATION (CA) | 2014-06-26 | — | — | US | disclosed |
| US-20130178512-A1 | CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES | ALNYLAM PHARMACEUTICALS, INC (US) | 2013-07-11 | — | — | US | disclosed |
| US-8450467-B2 | Carbohydrate conjugates as delivery agents for oligonucleotides | ALNYLAM PHARMACEUTICALS, INC. (US) | 2013-05-28 | — | — | US | disclosed |
| US-20120136042-A1 | CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES | ALNYLAM PHARMACEUTICALS, INC (US) | 2012-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130178512-A1 | CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES | LPXN, ZYX, OSTC | PTPN1 1551/4885PTPN2 1744/4885PTPN6 2107/4885 |
| US-20150119445-A1 | Carbohydrate Conjugates as Delivery Agents for Oligonucleotides | LPXN, ZYX, OSTC | PTPN1 1472/4885PTPN2 1634/4885PTPN6 1974/4885 |
| US-20140179761-A1 | TARGETING LIPIDS | LY96, ABHD10, APOB | PTPN1 3225/4885PTPN2 2608/4885PTPN6 3591/4885 |
| US-11666653-B2 | Carbohydrate conjugates as delivery agents for oligonucleotides | HAVCR2, B3GAT3, CSGALNACT1 | PTPN1 2680/4885PTPN2 2398/4885PTPN6 2010/4885 |
| US-20150011615-A1 | Carbohydrate Conjugates as Delivery Agents for Oligonucleotides | LPXN, ZYX, OSTC | PTPN1 1542/4885PTPN2 1719/4885PTPN6 2070/4885 |
| US-20150119444-A1 | Carbohydrate Conjugates as Delivery Agents for Oligonucleotides | LPXN, ZYX, OSTC | PTPN1 1542/4885PTPN2 1719/4885PTPN6 2070/4885 |
| US-20120136042-A1 | CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES | LPXN, ZYX, OSTC | PTPN1 1551/4885PTPN2 1744/4885PTPN6 2107/4885 |
| US-20160375137-A9 | TARGETING LIPIDS | LY96, ABHD10, APOB | PTPN1 3225/4885PTPN2 2608/4885PTPN6 3591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.